LILRB1 and in situ carcinoma: In multivariate analysis, Concurrent CIS (HR 4.83, p = 0.006), multiplicity (HR 2.46, p = 0.02) and CD8+ILT2+ T cell population proportions (HR 7.86 for high level patients, p = 0.02) remained significant.